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Figure 1. MRI/MRV head and brain with sinus thrombosis involving the right internal jugular vein (A), sigmoid sinus (B) and entire right transverse sigmoid sinus (C).
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extension and speciﬁcally, no clot on the central venous
catheter. Patient was started on anticoagulation after which
her mentation improved gradually over several weeks.
Follow up MRI/MRV after two weeks of anticoagulation
showed persistence of the dural clot, but no extension. The
patient was discharged to the outpatient environment with
continued thrombosis on prolonged therapy and is currently
D+145 from transplant.
Patients undergoing stem cell transplantation (SCT) have
known risk factors for the development of VTE including the
underlying malignancy, chemotherapy regimens, immobility
during hospitalization and the use of central venous cathe-
ters. CVST is an unusual complication following SCT and was
heralded in this case by both dramatic clinical features and
subtle ﬁndings on imaging. It is unclear if CVST is extremely
rare or under-diagnosed post-transplant, and is a possible
element in the differential diagnosis of confusion in this
setting. Once detected, the dural thrombus persisted despite
prolonged anti-coagulation and steady improvement of pa-
tient’s sentinel symptoms.150
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Myeloma (MM) Patients after Autologous Stem Cell
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Background: Preliminary data presented by our group at the
2014 ASBMTmeeting suggested a correlation between higher
CD34+ Cell-Dose Infused (CD34-CDI) during ASCTand shorter
time to ALC recovery for MM patients (pts). This updated
analysis which includes additional pts with longer follow-up
supports our prior results, and suggests a correlation between
higher CD34-CDI and decreased incidence of infections.
Methods: From 1/2012-1/2014, 21 consecutive MM pts who
had undergone ASCT were evaluated retrospectively to
determine the impact of CD34-CDI on ALCs and infectious
events. During the ﬁrst 100 days post-ASCT, all infectious
complications were noted and ALCs collected. Overall sur-
vival and progression free survival were monitored. ALC re-
covery was deﬁned as the ﬁrst day of three consecutive
measurements for the cutoff values: ALC  800, ALC  1000,and ALC  1500. Cox proportional hazard models were
applied to evaluate the association of CD34-CDI to ALC re-
covery. The signiﬁcance of the associationwas assessed using
the Log Rank Test since no competing risks were identiﬁed.
Additionally, the Nonparametric Wilcoxon Rank Sum Test
was used to determine the relationship between CD34-CDI
and the development of any infectious events.
Results: Of the 21 patients, 81% were male, 19% were female.
Median age was 62 years (range 45-71). Majority (62%) had
IgG MM and kappa light chain restriction (86%). Approxi-
mately 62% had ISS Stage II/III disease. Patients who had
received a higher CD34-CDI were more likely to achieve ALC
 800 (p¼0.040) and ALC  1000 (p¼0.021). For ALC re-
covery deﬁned as ALC  1500, no statistical signiﬁcance was
observed (p¼0.27). When CD34-CDI was < 4x106 cells/kg,
median times to ALC  800 and ALC  1000 were 33.5 and
41.5 days respectively, and were 19 and 22 days when CD34-
CDI was > 4x106 cells/kg. Pts without infections tended to
have higher CD34-CDI compared to those pts with infections
(p¼0.0452). Five of six pts with CD34-CDI < 4x106 cells/kg,
and three of 15 pts with CD34-CDI > 4x106 cells/kg devel-
oped at least one bacterial infectious complication. Among
pts who received CD34-CDI < 4x106 cells/kg, 60% of in-
fections (9 out of 15 events) occurred. With 17 months (mo)
of median follow-up (range 9-30 mo), ﬁve pts have relapsed
and one death has occurred. Four of ﬁve relapses, and the one
death received CD34-CDI > 4x106 cells/kg.
Conclusion: Higher CD34-CDI (> 4x106 cells/kg) may
shorten time to ALC recovery and limit infectious complica-
tions. Most relapses to date occurred in pts transplanted with
CD34-CDI > 4x106 cells/kg, raising the question of product
contamination with higher cell-doses. Additional follow-up
and larger prospective trials are needed to further deﬁne
optimal CD34-CDI that balances the beneﬁts of shortened
time to ALC recovery, minimizing infectious complications,
and decreasing risk of product contamination.
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In Vivo Purging May Not be Required in the Era of
Universal Use of Rituximab Containing Chemo-
Immunotherapy in Patients with Follicular and Mantle
Cell Lymphoma: A Single Center Experience
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Table 1
Comparison of Demographic Data, Mobilization Characteristics and Post
Transplant Outcome in Patients Using Meloxicam + G-CSF Compared with
Historical Controls
Variables Meloxicam +





Median age (yr) 51 (25-63) 50 (18-65) .902
Sex M:F 20:5 36:14 .577
Diagnosis
MM 15 (60%) 32 (64%)
NHL/HD 8 (32%) 14 (28%)
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S136Kansas Medical Center, Westwood, KS; 5 Blood and Marrow
Transplant, University of Kansas Med Ctr MS 5003, Westwood,
KS; 6 BMT Program/Division of Hematology-Oncology,
University of Kansas Medical Center, Westwood, KS
Introduction: Although rituximab containing chemotherapy
regimens have improved response rates in B-cell lym-
phomas, a signiﬁcant percentage of patients will eventually
relapse. Autologous stem cell transplantation (Auto SCT) may
provide long-term remission in some of these patients. Tu-
mor contamination of harvested stem cell graft has been
postulated as a reason for relapse after Auto SCT. Single agent
rituximab has been used for in-vivo purging of CD20+ tumor
cells with positive results. In this study, we aimed to evaluate
whether use of rituximab based in-vivo purging is still
beneﬁcial in the era of universal use of rituximab containing
chemotherapy in patients with follicular (FL) or mantle cell
lymphoma (MCL).
Materials and Methods: Twenty consecutive patients with a
diagnosis of relapsed CD20+ FL or transplant eligible MCL
were included in this study. All patients received rituximab
containing chemotherapy. Restaging was done after
completion of chemotherapy and those with chemo-sensi-
tive disease (n¼14) were considered for Auto SCT. Polymer-
ase Chain Reaction (PCR) analysis for bcl2 and bcl1 were
done on apheresis products from patients with FL and MCL
respectively. In-vivo purging with single agent rituximab
was planned if any stem cell product were to be found PCR
positive prior to Auto SCT.
Results: A total of 19 patients were eligible for analysis. Pa-
tient characteristics are shown in the accompanying table.
The bcl-2/bcl-1 status of the graft was available in 14 patients
(FL; n¼10 and MCL; n¼4). The stem cell products in all 14
patients tested negative by PCR for both bcl2 (FL) and
bcl1(MCL). None of these patients required additional rit-
uximab treatment for in-vivo purging. Eleven patients (FL;
n¼7 and MCL; n¼4) underwent Auto SCT. Three patients
with FL opted for “Harvest and Hold” approach and delayed
transplantation. Median (range) PFS and OS of patients with
FL undergoing Auto SCT were 2 yrs. (9 mo-5 y) and 3 yrs. (2-5
y) and those with MCL were 3 yrs. (2-4y) and 4 yrs. (2-5 y)
respectively (median duration of follow up-3yrs.).
Discussion: In this small cohort of patients with FL and MCL
treated by R-chemotherapy, 100% of the harvested stem cell
products were tumor free by PCR analysis. Our ﬁndings
suggest that with universal use of rituximab containing
chemo-immunotherapy in patients with FL and MCL, addi-
tional in-vivo purging may not be required. We may also
conclude that persistence of residual/refractory disease afterTable 1
Patient Characteristics
Patient characteristics














PR (Chemo sensitive) 2auto SCT rather than tumor contamination of the graft was
the most likely cause of relapse in this cohort.
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The Addition of Meloxicam to G-CSF Is Associated with
Good Mobilization Rates, Faster Engraftment and
Reduced Toxicity and Hospital Stay after Autologous Stem
Cell Transplantationea Phase II Study
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N.A. Fouzia, Alok Srivastava, Vikram Mathews. Department of
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Mobilization failure is seen in 10-15% of patients undergoing
G-CSF or chemo mobilization and the use of plerixafor is
limited by its cost in developing countries. This phase II study
is being undertaken to study whether the addition of
Meloxicam to standard G-CSF will improve rates of mobili-
zation (CTRI/2014/06/004671). Patients received Meloxicam
15mg once daily for 5 days from Day -7 to -3 and G-CSF 5 mg/
kg BD from Day -4 to -1. Target CD34 dose was 4 x 106 CD34/
Kg. Patients with myeloma proceeded immediately to an
autologous transplant (auto SCT) with single agent
melphalan conditioning while patients with lymphoma and
AML had cryopreservation of harvest followed by using
either BEAM or BuCy2 conditioning.
Between November 2013 and July 2014, 25 patients
(20 males and 5 females) with a median age of 51 years
(range: 25-63) received meloxicamwith G-CSF. There was no
toxicity in any of the patients during the 5 days of adminis-
tration of meloxicam. A cell dose of > 2 x 106 CD34/kg was
achieved in 21 (84%) with a cell dose of > 3 x 106 CD34/kg
being achieved in a single harvest in 15 (60%). Four patients
needed additional cyclophosphamide mobilization to
achieve the target cell doses. Analysis of peripheral blood
CD34 counts revealed that 20 (80%) had counts > 20/ul onAPML/AML 2 (8%) 4 (8%)
Successful mobilization (>2 
106 CD34/kg after 2 harvests)
21 (84%) 42 (84%) 1.000
CD34 > 5  106/kg 12 (48%) 18 (36%) .138
CD34 > 3  106/kg 20 (80%) 32 (64%) .191
Conditioning regimen
High dose melphalan 15 (60%) 32 (64%)
BEAM 8 (32%) 14 (28%)
Bu/Cy2 2 (8%) 4 (8%)
ANC > 500/cumm (d) 11.09  0.53 11.53  0.92 .044
ANC > 1000/cumm (d) 11.61  0.45 11.95  0.99 .216
Platelet count > 20000/cumm (d) 14.7  4.5 16.4  6.3 .291
Platelet count > 50000/cumm (d) 17.4  7.5 24.7  19.3 .143
Platelet count> 100000/cumm (d) 23.1  11.9 51.2  58.2 .025
Number of red cell units
transfused
1.19  1.1 2.31  2.45 .031
Number of platelet units
transfused
12  9.1 17  16 .327
No of pts with grade III-IV toxicity 7/21 (31.8%) 33/47 (59.5%) .040
Duration of hospital stay from
day 0 (d)
16  3.3 20  7.3 .025
